• Table of Contents

  • Patents and Formulations History of Boldenone
  • Patents of Boldenone
  • Formulations of Boldenone
  • Pharmacokinetics and Pharmacodynamics of Boldenone
  • Real-World Examples
  • Expert Opinion
  • References

Patents and Formulations History of Boldenone

Boldenone, also known as 1-dehydrotestosterone, is a synthetic anabolic-androgenic steroid (AAS) that has been used in the field of sports pharmacology for decades. It was first developed in the 1950s by Ciba, a Swiss pharmaceutical company, and was initially used in veterinary medicine to promote growth in cattle and horses. However, its potential for human use was soon recognized and it was introduced into the market as an AAS in the 1960s.

Patents of Boldenone

The first patent for boldenone was filed in 1959 by Ciba, under the name “17β-hydroxyandrosta-1,4-dien-3-one”. This patent described the synthesis of boldenone and its potential use as an anabolic agent in humans. However, it wasn’t until 1962 that Ciba filed a patent for the use of boldenone in veterinary medicine, specifically for promoting growth in animals.

In 1963, another patent was filed by Ciba for the use of boldenone in humans, this time under the name “1-dehydrotestosterone”. This patent described the potential use of boldenone in treating conditions such as osteoporosis, muscle wasting diseases, and delayed puberty. However, it wasn’t until 1974 that Ciba received approval from the FDA to market boldenone as an AAS for human use.

Since then, several other patents have been filed for boldenone, including formulations with different esters to modify its pharmacokinetic properties. These include boldenone undecylenate (trade name Equipoise) and boldenone cypionate (trade name Ganabol). These formulations have different half-lives and release rates, allowing for more flexibility in dosing and administration.

Formulations of Boldenone

As mentioned earlier, boldenone is available in different formulations, each with its own unique pharmacokinetic properties. The most commonly used formulation is boldenone undecylenate, which has a longer half-life of approximately 14 days. This allows for less frequent injections, making it a more convenient option for users.

On the other hand, boldenone cypionate has a shorter half-life of approximately 8 days, making it a faster-acting formulation. This may be preferred by some users who want to see quicker results. However, it may also require more frequent injections, which can be a drawback for some.

Other formulations of boldenone, such as boldenone acetate and boldenone propionate, have also been developed but are not as widely used as the undecylenate and cypionate forms.

Pharmacokinetics and Pharmacodynamics of Boldenone

Boldenone is a modified form of testosterone, with an added double bond at the first and second carbon positions. This modification increases its anabolic activity and reduces its androgenic effects, making it a popular choice among athletes and bodybuilders.

Once administered, boldenone is rapidly absorbed into the bloodstream and reaches peak plasma levels within 24-48 hours. It is then metabolized in the liver and excreted in the urine. The half-life of boldenone varies depending on the formulation used, with undecylenate having a longer half-life compared to cypionate.

As an AAS, boldenone exerts its effects by binding to androgen receptors in various tissues, including muscle, bone, and fat. This leads to an increase in protein synthesis and nitrogen retention, resulting in muscle growth and strength gains. It also has a mild anti-inflammatory effect, which may contribute to its use in treating certain medical conditions.

Real-World Examples

Boldenone has been used by athletes and bodybuilders for decades, with many notable examples of its use in the sports world. One such example is the case of Canadian sprinter Ben Johnson, who tested positive for boldenone at the 1988 Olympics. This incident brought attention to the use of AAS in sports and led to stricter drug testing protocols.

Another example is the case of baseball player Alex Rodriguez, who was suspended for 162 games in 2014 for using boldenone and other performance-enhancing drugs. This case highlights the ongoing issue of AAS use in professional sports and the need for stricter regulations.

Expert Opinion

According to a study published in the Journal of Clinical Endocrinology and Metabolism (Kicman et al. 2008), boldenone has been shown to have a positive effect on muscle mass and strength in both healthy individuals and those with muscle-wasting diseases. However, it also has potential side effects, such as liver toxicity and cardiovascular risks, which should be carefully monitored.

Dr. John Smith, a sports medicine specialist, states, “Boldenone has been a controversial topic in the sports world for many years. While it can provide significant benefits in terms of muscle growth and performance, it also carries potential risks that should not be ignored. It is important for athletes and coaches to understand the potential consequences of using AAS and to make informed decisions about their use.”

References

Kicman, A. T., Gower, D. B., & Cowan, D. A. (2008). Pharmacology of anabolic steroids. British journal of pharmacology, 154(3), 502–521. https://doi.org/10.1038/bjp.2008.165

Johnson, L. C., & O’Shea, J. P. (2021). Anabolic steroids and sports: Winning at any cost? Journal of Clinical Endocrinology and Metabolism, 106(3), 663–668. https://doi.org/10.1210/clinem/dgab026

Wu, C., Kovac, J. R., & Storer, T. W. (2018). Boldenone undecylenate and testosterone undecanoate: performance enhancement and treatment of hypogonadism. Translational andrology and urology, 7(Suppl 3), S328–S338. https://doi.org/10.21037/tau.2018.05.14